BioPharmSignal logoBioPharmSignal

Biotech News

Gyre Therapeutics to Participate in Upcoming September Investor Conferences

Gyre Therapeutics (GYRE)Gyre TherapeuticsCommercial

SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre, Gyre Therapeutics or the Company) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with operations in the United States and China, today announced that Company management will participate in the

Related news

GYREGyre Therapeutics2026-07-16 20:05 EST

Gyre Therapeutics Appoints Three New Members to its Board of Directors

VERAVera Therapeutics2026-09-01 11:30 EST

Vera Therapeutics to Participate at Upcoming Investor Conferences

KYTXKyverna Therapeutics2026-07-27 12:00 EST

Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel

KYTXKyverna Therapeutics2026-06-22 12:00 EST

Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition

KYMRKymera2026-09-02 20:01 EST

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

NRIXNurix Therapeutics2026-09-01 12:00 EST

Nurix Therapeutics to Participate in Upcoming September Investor Conferences

GYREGyre Therapeutics2026-08-07 11:00 EST

Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update

GPCRStructure Therapeutics2026-09-03 11:30 EST

Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences

AVTXAvalo Therapeutics2026-09-03 11:00 EST

Avalo Therapeutics to Participate in Upcoming Investor Conferences

EQEquillium, Inc.2026-09-02 12:30 EST

Equillium to Participate in Upcoming Investor Conferences

View all latest news

Gyre Therapeutics

Fibrosis and Inflammation Franchise Gyre Therapeutics is a commercial-stage biopharmaceutical company operating in the United States and China. Its small-molecule portfolio is centered on organ fibrosis and inflammatory diseases. Commercial Products in China Gyre Pharmaceuticals commercializes ETUARY, a pirfenidone therapy for idiopathic...

Recent company news

GYREGyre Therapeutics2026-09-03 11:00 EST

Gyre Therapeutics to Participate in Upcoming September Investor Conferences

GYREGyre Therapeutics2026-08-07 11:00 EST

Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update

GYREGyre Therapeutics2026-07-16 20:05 EST

Gyre Therapeutics Appoints Three New Members to its Board of Directors

GYREGyre Therapeutics2026-05-12 20:06 EST

Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment

GYREGyre Therapeutics2026-05-07 10:00 EST

Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update

Stock data

Close
7.18 USD
Market cap
539.48M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States